Abstract: Objective To assess the difference in changes of symptoms, effective rate and full remission rate between Ziprasidone combining antidepressants and single antidepressant in the treatment of treatment-resistant depression（TRD）. Methods 8 studies meeting our criteria were analyzed by evidence-based medicine, comparing the difference in changes of symptoms, efficacy rate and full remission rate. Results The lower depressive symptoms in Ziprasidone group comparing controls were found （Z=15.84, P< 0.01, WMD=-3.83, 95%CI -4.30~-3.36）. The very significant higher effective rate and full remission rate in Ziprasidone group comparing controls were found （63.3% vs. 45.7%, Z=4.31, P< 0.000 1, OR=2.25, 95%CI 1.56~3.26; 35.6% vs. 19.1%, Z=4.44, P< 0.000 01, OR=2.58, 95%CI 1.70~3.91）. Conclusion It can promote therapeutic efficacy of patients with treatment-resistant depression, combining antidepressants with Ziprasidone.